New combo prostate cancer therapy shown safe, effective in trial

Two targeted treatments reduced PSA levels in patients with prostate cancer and had fewer side effects than traditional therapies.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news

Related Links:

y S Abstract An important requirement to decrease the side effects of chemotherapy drugs is to develop nanocarriers with precise biological functions. In this work, a set of glyconanoparticles was prepared via self-assembly of amphiphilic glycoblock copolymers for the targeted delivery of a hydrophobic chemotherapy drug. Well-defined glycoblock copolymers that consist of 1,1-di-tert-butyl 3-(2-(metyloyloxy)ethyl)-butane-1,1,3-tricarboxylate (MAETC) together with three different protected-sugar moieties (β-D-glucopyranoside, β-D-mannopyranoside, and β-L-fucopyranoside) were synthesized by using RAFT ...
Source: Biomacromolecules - Category: Biochemistry Authors: Tags: Biomacromolecules Source Type: research
Patient decision aids (PDAs) can support the treatment decision making process and empower patients to take a proactive role in their treatment pathway while using a shared decision-making (SDM) approach makin...
Source: BMC Medical Informatics and Decision Making - Category: Information Technology Authors: Tags: Technical advance Source Type: research
Macrophages with tumor-tropic migratory properties can serve as a cellular carrier to enhance the efficacy of anti neoplastic agents. However, limited drug loading (DL) and insufficient drug release at the tum...
Source: Journal of Nanobiotechnology - Category: Nanotechnology Authors: Tags: Research Source Type: research
AbstractProstate cancer ranks the second in incidence and the fifth in mortality cancer in male globally. Citrus polymethoxyflavonoids (PMFs), such as tangeretin (PMF1), have been found to exhibit various biological activities. Here, we evaluated the inhibitory effects and mechanism of synthetic 5,4 ′-didemethyltangeretin (PMF2) on human prostate cancer LNCaP cells. We found that PMF2 inhibited the growth of LNCaP cells (GI50 14.6  μM) more strongly than PMF1, and it was less cytotoxic against the normal human prostate RWPE-1 cells. PMF2 upregulated Bad and Bax, downregulated Bcl-2, and activated caspase-3 an...
Source: The AAPS Journal - Category: Drugs & Pharmacology Source Type: research
An interdisciplinary team of UCLA scientists has found that small cell neuroendocrine cancers from a range of tissues have a common molecular signature and share drug sensitivities with blood cancers. The discoveries could improve the diagnoses of these aggressive cancers and lead to the development of new treatments that build upon the lessons learned from successful blood cancer therapies.The study, led by senior authors  Thomas Graeber and Dr. Owen Witte,  both of the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and Jonsson Comprehensive Cancer ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Smoking tobacco takes a heavy toll on the immune system --a toll that can be...Read more on AuntMinnie.comRelated Reading: SNMMI: PET spotlights link between Down syndrome, Alzheimer's SNMMI: PET ligand can diagnose brain disorder before autopsy SNMMI: Technetium radiotracer tracks rheumatoid arthritis SNMMI: FDG-PET/MRI improves pain diagnosis, management SNMMI: PSMA-PET helps guide prostate cancer therapy
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
(Society of Nuclear Medicine and Molecular Imaging) New prostate cancer research shows that adding an interim scan during therapy can help guide a patient's treatment. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant predictive value for patient survival. The research was presented at the 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
ANAHEIM, CA - Adding an interim prostate-specific membrane antigen (PSMA)-PET...Read more on AuntMinnie.comRelated Reading: Could Ga-68 PSMA PET become essential for prostate cancer? Ga-68 PSMA PET/CT for prostate wins Australian favor Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Novel nanoSPECT/CT radionuclide could aid cancer therapy SNMMI: Early prostate cancer therapy extends lives
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
ANAHEIM, CA - Adding an interim prostate-specific membrane antigen (PSMA)-PET...Read more on AuntMinnie.comRelated Reading: Could Ga-68 PSMA PET become essential for prostate cancer? Ga-68 PSMA PET/CT for prostate wins Australian favor Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Novel nanoSPECT/CT radionuclide could aid cancer therapy SNMMI: Early prostate cancer therapy extends lives
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
The purpose of this study was to develop preclinical evaluation of a novel radiolabeled gonadotropin ‐releasing hormone (GnRH) receptor targeting peptide for prostate cancer therapy. The new antiproliferative agent of GnRH‐I analogue was developed on the basis of the D‐Trp6‐GnRH‐I scaffold, and in vivo pharmacokinetics and receptor binding affinity were enhanced by the substitution of Gly‐NHNH2 for Gly ‐NH2 at position 10 in D ‐Trp6‐GnRH‐I. To evaluate177Lu ‐DOTA‐triptorelin‐hydrazide as radionuclide therapy of tumor, the quality control tests and preclinical stage assessment were carried out. Sol...
Source: Journal of Labelled Compounds and Radiopharmaceuticals - Category: Biochemistry Authors: Tags: RESEARCH ARTICLE Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Prostate Cancer